Xolair denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for xolair are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Xolair: Quantity Limits Exceeded

UHC applies quantity limits to Xolair (omalizumab) based on its published medical policy. These limits typically reflect dosing ranges described in the FDA-approved prescribing information, which ties dose and frequency to body weight and IgE levels (for asthma indications) or to a fixed schedule (for other indications). A quantity-limits denial means your prescription as written exceeds the amount UHC will cover under its standard policy — not necessarily that the drug is inappropriate for you.

## Why This Is Appealable

Quantity-limit denials are among the most commonly overturned. If your prescriber has written a dose that is within the FDA-approved label range but above UHC's default quantity limit, a medical exception can be requested. The appeal should show that the prescribed quantity is consistent with the FDA label and with the applicable clinical guideline (for example, guidance from the relevant allergy, asthma, or immunology specialty society), and that your specific clinical characteristics — which your prescriber can document — support the prescribed regimen.

## Federal Appeal Framework

• Internal appeal: File within the timeframe on your denial notice (usually 180 days). UHC must decide post-service quantity appeals within 60 days; prospective appeals within 30 days; urgent appeals within 72 hours.
• External review: Available after the internal appeal is exhausted, generally within four months of the final internal denial under ACA §2719 / ERISA §503 external review rules.

## Documentation to Collect

1. Current FDA prescribing label — download the Xolair full prescribing information and identify the dosing table applicable to your indication, weight, and (if relevant) IgE level. Your prescriber should confirm the prescription is within that labeled range. 2. UHC quantity-limit policy — obtain UHC's current medical policy for Xolair and note the exact quantity limit they apply. 3. Clinical justification — chart documentation of the measurements (weight, lab values as applicable) that drive the prescribed dose, with your provider's explanation of why the prescribed quantity is medically necessary. 4. Prescriber letter — explicitly stating the clinical basis for the prescribed quantity and referencing the FDA label dosing table. 5. Prior-treatment outcomes — if you were previously on a lower quantity and it was insufficient, document those outcomes.

## Criteria-Mapping Structure

Create a table: left column lists each quantity-limit criterion from UHC's policy; right column cites the specific chart fact, measurement, or label reference that justifies the prescribed amount. Attach the relevant page of the FDA prescribing information as an exhibit.

## Manufacturer Support

Genentech's patient support program for Xolair may be able to provide bridge supply during the appeals process. Ask your specialty pharmacy or prescriber's office to connect you with this resource.